AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors
AIM ImmunoTech (NYSE American: AIM) has secured a significant patent in Japan for its cancer therapy combining Ampligen® (Rintatolimod) with checkpoint inhibitors, valid through 2039. The patent covers multiple cancer types and strengthens AIM's position in the world's third-largest pharmaceutical market.
The broad patent claims encompass treatments for pancreatic, skin, colorectal, ovarian, melanoma, breast, head and neck, bladder, renal cell, and lung cancers. AIM holds similar patents in the U.S. (expires 2039) and Netherlands (expires 2039) for Ampligen combination therapies.
The company is currently conducting a Phase 2 trial with AstraZeneca, combining Ampligen with durvalumab for metastatic pancreatic cancer, showing promising survival results. Additionally, a Phase 2 study with Merck combining Ampligen with Keytruda for advanced recurrent ovarian cancer awaits final data reports.
AIM ImmunoTech (NYSE American: AIM) ha ottenuto un importante brevetto in Giappone per la sua terapia contro il cancro che combina Ampligen® (Rintatolimod) con inibitori dei checkpoint, valido fino al 2039. Il brevetto copre molteplici tipi di tumore e rafforza la posizione di AIM nel terzo mercato farmaceutico mondiale.
Le ampie rivendicazioni del brevetto includono trattamenti per tumori pancreatici, della pelle, del colon retto, ovarici, melanoma, mammella, testa e collo, vescica, cellule renali e polmone. AIM detiene brevetti simili negli Stati Uniti (scadenza 2039) e nei Paesi Bassi (scadenza 2039) per terapie di combinazione con Ampligen.
L'azienda sta attualmente conducendo uno studio di fase 2 con AstraZeneca, combinando Ampligen con durvalumab per il cancro pancreatico metastatico, con risultati di sopravvivenza promettenti. Inoltre, uno studio di fase 2 con Merck che combina Ampligen con Keytruda per il cancro ovarico avanzato ricorrente aspetta i dati finali.
AIM ImmunoTech (NYSE American: AIM) ha obtenido una patente importante en Japón para su terapia contra el cáncer que combina Ampligen® (Rintatolimod) con inhibidores de puntos de control, válida hasta 2039. La patente cubre múltiples tipos de cáncer y fortalece la posición de AIM en el tercer mercado farmacéutico más grande del mundo.
Las amplias reivindicaciones de la patente abarcan tratamientos para cánceres de páncreas, piel, colorrectal, ovario, melanoma, mama, cabeza y cuello, vejiga, células renales y pulmón. AIM posee patentes similares en Estados Unidos (vigente hasta 2039) y en Países Bajos (vigente hasta 2039) para terapias de combinación con Ampligen.
La empresa está llevando a cabo un ensayo de fase 2 con AstraZeneca, combinando Ampligen con durvalumab para cáncer de páncreas metastásico, con resultados de supervivencia prometedores. Además, un estudio de fase 2 con Merck que combina Ampligen con Keytruda para cáncer de ovario avanzado recurrente espera los informes finales de datos.
AIM ImmunoTech (NYSE American: AIM)은 암 치료제 Ampligen® (Rintatolimod)을 체크포인트 억제제와 결합한 치료법에 대해 일본에서 2039년까지 유효한 중요한 특허를 확보했습니다. 이 특허는 여러 암 유형을 포괄하며 세계에서 세 번째로 큰 제약 시장에서 AIM의 입지를 강화합니다.
특허의 광범위한 청구 항은 췌장암, 피부암, 대장암, 난소암, 흑색종, 유방암, 두경부암, 방광암, 신세포암, 폐암 치료를 포함합니다. AIM은 미국(2039년 만료)과 네덜란드(2039년 만료)에서도 Ampligen 조합 요법에 대한 유사한 특허를 보유하고 있습니다.
회사는 현재 AstraZeneca와 함께 2상 시험을 진행 중이며, Ampligen과 durvalumab을 결합한 전이성 췌장암 치료에서 생존 결과가 고무적입니다. 또한 Merck와의 Ampligen + Keytruda 조합 난소암 진행성 재발에 대한 2상 연구의 최종 데이터 보고를 기다리고 있습니다.
AIM ImmunoTech (NYSE American: AIM) a obtenu un brevet important au Japon pour son traitement anticancéreux associant à des inhibiteurs de points de contrôle, valable jusqu’en 2039. Le brevet couvre plusieurs types de cancer et renforce la position d’AIM sur le troisième marché pharmaceutique mondial.
Les revendications larges du brevet couvrent des traitements pour cancers du pancréas, de la peau, colorectal, ovarien, mélanome, sein, tête et cou, vessie, carcinomes rénaux et poumons. AIM détient des brevets similaires aux États-Unis (exp. 2039) et aux Pays-Bas (exp. 2039) pour des thérapies de combinaison Ampligen.
L’entreprise mène actuellement un essai de phase 2 avec AstraZeneca, associant Ampligen à durvalumab pour un cancer du pancréas métastatique, avec des résultats de survie prometteurs. De plus, une étude de phase 2 avec Merck associant Ampligen à Keytruda pour un cancer ovarien avancé récurrent attend les rapports finaux.
AIM ImmunoTech (NYSE American: AIM) hat in Japan ein bedeutendes Patent für seine Krebstherapie gesichert, die mit Checkpoint-Inhibitoren kombiniert, gültig bis 2039. Das Patent deckt mehrere Krebsarten ab und stärkt AIMs Stellung im weltweit dritgrößten Pharma-Markt.
Die breiten Patentansprüche umfassen Behandlungen für Pankreaskrebs, Hautkrebs, kolorektalen Krebs, Ovarialkrebs, Melanom, Brustkrebs, Kopf- und Halskrebs, Blasenkrebs, Nierenzellkrebs und Lungenkrebs. AIM hält ähnliche Patente in den USA (Laufzeit bis 2039) und den Niederlanden (2039) für Ampligen-Kombinationstherapien.
Das Unternehmen führt derzeit eine Phase-2-Studie mit AstraZeneca durch, bei der Ampligen mit Durvalumab zur metastatischen Bauchspeicheldrüsenkrebskombination verwendet wird, mit vielversprechenden Überlebensdaten. Zusätzlich wartet eine Phase-2-Studie mit Merck, die Ampligen mit Keytruda zur fortgeschrittenen rezidivierenden Eierstockkrebs kombiniert, auf abschließende Datenausberichte.
AIM ImmunoTech (NYSE American: AIM) حصلت على براءة اختراع مهمة في اليابان لعلاجها من السرطان الذي يجمع بين Ampligen® (Rintatolimod) ومثبطات نقاط التفتيش، وبالصلاحية حتى 2039. تغطي البراءة عدة أنواع من السرطان وتعزز موقع AIM في ثالث أكبر سوق للأدوية في العالم.
تشمل المطالبات الواسعة للبراءة علاجات لـسرطانات البنكرياس والجلد والقولون المستقيم والمبيض والورم الميلانيني والثدي والرأس والرقبة والموْصٍة وخلية الكلية والرئة. تمتلك AIM براءات مماثلة في الولايات المتحدة (تنتهي في 2039) وهولندا (تنتهي في 2039) لعلاجات الدمج Ampligen.
تجري الشركة حالياً تجربة من المرحلة الثانية مع أسترازينكا، بجمع Ampligen مع دورفالوماب للمساعدة في سرطان البنكرياس المتقدم، مع نتائج بقاء واعدة. كما ينتظر تقرير البيانات النهائية لدراسة المرحلة الثانية مع Merck التي تجمع Ampligen مع Keytruda لسرطان المبيض المتقدم المتكرر.
AIM ImmunoTech (NYSE American: AIM) 已在日本获得一项重要专利，涉及将 Ampligen® (Rintatolimod) 与检查点抑制剂联合使用的癌症治疗，专利有效期至 2039 年。该专利覆盖多种癌症类型，提升 AIM 在全球第三大制药市场的地位。
广泛的专利权要求涵盖 胰腺癌、皮肤癌、结直肠癌、卵巢癌、黑色素瘤、乳腺癌、头颈癌、膀胱癌、肾细胞癌和肺癌 的治疗。AIM 在美国（到 2039 年到期）和荷兰（到 2039 年到期）也拥有类似的 Ampligen 组合疗法专利。
公司目前正与阿斯利康开展一个二期临床试验，将 Ampligen 与 durvalumab 结合用于转移性胰腺癌，生存率数据令人乐观。此外，与默沙东的另一项将 Ampligen 与 Keytruda 结合用于晚期复发性卵巢癌的二期研究，亦在等待最终数据报告。
- None.
- Final data from ovarian cancer study still pending
- Commercialization timeline and regulatory approvals remain uncertain
Insights
AIM strengthens global IP position with Japan patent for Ampligen-checkpoint inhibitor combo, extending protection in world's third-largest pharma market until 2039.
AIM ImmunoTech's new Japanese patent significantly bolsters their intellectual property portfolio by securing protection for combining Ampligen (rintatolimod) with checkpoint inhibitors through December 2039. The breadth of the patent is particularly impressive, covering multiple cancer types including pancreatic, skin, colorectal, ovarian, melanoma, breast, head and neck, bladder, renal cell, and lung cancers. The patent also encompasses specific dosing regimens, administration routes, and the synergistic effects observed with these combinations.
This Japan patent complements AIM's existing protections in the US (expiring August 2039) and Netherlands (expiring December 2039) for similar combination therapies. The strategic significance cannot be overstated – Japan represents the third-largest pharmaceutical market globally, with oncology being its fastest-growing therapeutic area.
The expanded protection creates multiple commercialization pathways. AIM can now confidently pursue licensing agreements and strategic partnerships in Japan without fear of patent circumvention. The timing aligns perfectly with their ongoing clinical development programs, including a Phase 2 trial with AstraZeneca combining Ampligen with durvalumab for metastatic pancreatic cancer, which has shown promising interim results for survival outcomes without significant toxicity.
For a smaller biotech company like AIM, this robust patent estate significantly enhances negotiating leverage for potential partnerships while providing clear exclusivity in major markets through 2039 – a substantial runway for commercialization should their clinical trials continue to show positive results.
Patent supports AIM’s strategy to expand international market protection, providing opportunities for licensing, collaborations, and long-term revenue growth
Japan is the third-largest pharmaceutical market globally, with oncology as the fastest-growing therapeutic area
OCALA, Fla., Sept. 25, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Japan Patent Office has issued a patent covering the Company’s proprietary use of Ampligen® (Rintatolimod) in combination with checkpoint inhibitors (anti-PD-1 or anti-PD-L1 antibodies) for the treatment of cancer.
“We remain committed to strengthening our global intellectual property protection for Ampligen as we continue to advance its clinical development. This Japan patent – which does not expire until December 20, 2039 – further strengthens our intellectual property portfolio in one of the world’s largest oncology markets and enhances exclusivity around combination therapies that address high-need cancer indications. Importantly, this patent further reinforces our ability to advance our clinical pipeline, secure strategic collaborations, and capture value in the growing global immuno-oncology sector. The scope of this patent enhances the value for any future strategic oncology transactions,” AIM ImmunoTech CEO Thomas K. Equels stated.
The allowed claims in Japan cover an agent for treating cancer consisting of Ampligen in combination with a checkpoint inhibitor. The claims are broad, encompassing multiple cancer types, including pancreatic cancer, skin cancer, colorectal cancer, ovarian cancer, melanoma, breast cancer/triple negative breast cancer, head and neck tumors, bladder cancer, renal cell carcinoma, and lung cancer. The claims also capture specific dosing regimens, administration routes, and synergistic therapeutic effects observed when Ampligen is combined with checkpoint inhibitors.
AIM also holds a U.S. patent (expires August 9, 2039) for methods involving use of Ampligen as part of a combination oncology therapy when paired with an anti-PD-L1 antibody and a patent in the Netherlands (expires December 19, 2039) for the use of Ampligen as a combination cancer therapy with checkpoint blockade inhibitors, such as Keytruda (pembrolizumab), Opdivo (nivolumab) and Imfinzi (durvalumab).
The combination of these compounds is designed to work synergistically to enhance the effectiveness of the treatment. AIM believes this novel approach could revolutionize the treatment landscape for cancers that have historically been challenging to treat, such as pancreatic cancer and advanced recurrent ovarian cancer. In fact, in collaboration with AstraZeneca, Ampligen is in a Phase 2 clinical trial combined with AstraZeneca’s durvalumab (an anti-PD-L1) for the treatment of metastatic pancreatic cancer. AIM recently released a DURIPANC Mid-Year Interim Clinical Progress Update showing promising signs of superior Progression-Free Survival and Overall Survival, as well as no significant toxicity.
Similarly, a Phase 2 study in collaboration with Merck Sharp & Dohme LLC in advanced recurrent ovarian cancer combing Ampligen with Keytruda has been completed and we expect the final data report within the next two months.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
Cautionary Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy for any indication. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@jtcir.com
FAQ
What is the significance of AIM ImmunoTech's new Japanese patent for Ampligen?
Which types of cancer are covered under AIM's new Japanese patent?
What are the current clinical trials involving AIM's Ampligen?
How long will AIM ImmunoTech's patent protection last in different regions?
What are the preliminary results from AIM's pancreatic cancer trial?
